API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fiercebiotech.com/biotech/cash-strapped-acer-sees-menopause-drug-flunk-phase-2-trial
https://www.globenewswire.com/news-release/2023/02/13/2606634/0/en/Acer-Therapeutics-Announces-Full-Enrollment-of-Phase-2a-Trial-of-ACER-801-Osanetant-for-Treatment-of-Moderate-to-Severe-Vasomotor-Symptoms-Associated-with-Menopause.html
https://www.globenewswire.com//news-release/2023/01/05/2583727/0/en/Acer-Therapeutics-Announces-Initiation-of-Two-Investigator-Sponsored-Trials-of-ACER-801-Osanetant-in-Men-with-Adenocarcinoma-of-the-Prostate.html
https://www.globenewswire.com/news-release/2022/10/06/2529532/0/en/Acer-Therapeutics-Announces-University-of-North-Carolina-Receives-Department-of-Defense-Grant-to-Support-the-Proposed-Investigator-Sponsored-OASIS-Trial-of-ACER-801-Osanetant-to-Re.html
https://www.globenewswire.com/news-release/2022/10/05/2528698/0/en/Acer-Therapeutics-Announces-Expansion-of-ACER-801-osanetant-Development-Indications-to-Include-Post-Traumatic-Stress-Disorder.html